These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
304 related articles for article (PubMed ID: 28434191)
1. The effect of parotid gland-sparing intensity-modulated radiotherapy on salivary composition, flow rate and xerostomia measures. Richards TM; Hurley T; Grove L; Harrington KJ; Carpenter GH; Proctor GB; Nutting CM Oral Dis; 2017 Oct; 23(7):990-1000. PubMed ID: 28434191 [TBL] [Abstract][Full Text] [Related]
2. Impact of salivary gland dosimetry on post-IMRT recovery of saliva output and xerostomia grade for head-and-neck cancer patients treated with or without contralateral submandibular gland sparing: a longitudinal study. Wang ZH; Yan C; Zhang ZY; Zhang CP; Hu HS; Tu WY; Kirwan J; Mendenhall WM Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1479-87. PubMed ID: 20934262 [TBL] [Abstract][Full Text] [Related]
3. Recovery of Salivary Function: Contralateral Parotid-sparing Intensity-modulated Radiotherapy versus Bilateral Superficial Lobe Parotid-sparing Intensity-modulated Radiotherapy. Miah AB; Gulliford SL; Morden J; Newbold KL; Bhide SA; Zaidi SH; Hall E; Harrington KJ; Nutting CM Clin Oncol (R Coll Radiol); 2016 Sep; 28(9):e69-e76. PubMed ID: 26994893 [TBL] [Abstract][Full Text] [Related]
4. Reducing xerostomia after chemo-IMRT for head-and-neck cancer: beyond sparing the parotid glands. Little M; Schipper M; Feng FY; Vineberg K; Cornwall C; Murdoch-Kinch CA; Eisbruch A Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):1007-14. PubMed ID: 22056067 [TBL] [Abstract][Full Text] [Related]
5. Objective and subjective assessment of xerostomia in patients of locally advanced head-and-neck cancers treated by intensity-modulated radiotherapy. Lal P; Nautiyal V; Verma M; Yadav R; Maria Das KJ; Kumar S J Cancer Res Ther; 2018; 14(6):1196-1201. PubMed ID: 30488829 [TBL] [Abstract][Full Text] [Related]
6. A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results. Chao KS; Deasy JO; Markman J; Haynie J; Perez CA; Purdy JA; Low DA Int J Radiat Oncol Biol Phys; 2001 Mar; 49(4):907-16. PubMed ID: 11240231 [TBL] [Abstract][Full Text] [Related]
7. A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing. Rosenthal DI; Chambers MS; Weber RS; Eisbruch A Semin Oncol; 2004 Dec; 31(6 Suppl 18):25-8. PubMed ID: 15726519 [TBL] [Abstract][Full Text] [Related]
8. Xerostomia, salivary characteristics and gland volumes following intensity-modulated radiotherapy for nasopharyngeal carcinoma: a two-year follow up. Sim C; Soong YL; Pang E; Lim C; Walker GD; Manton DJ; Reynolds EC; Wee J Aust Dent J; 2018 Jun; 63(2):217-223. PubMed ID: 29569726 [TBL] [Abstract][Full Text] [Related]
9. Effect of bilateral superficial parotid gland sparing IMRT on xerostomia and QOL: A prospective study. Madhwapathy KS; Manur J J Cancer Res Ther; 2024 Jul; 20(5):1400-1405. PubMed ID: 39412906 [TBL] [Abstract][Full Text] [Related]
10. Preservation of oral health-related quality of life and salivary flow rates after inverse-planned intensity- modulated radiotherapy (IMRT) for head-and-neck cancer. Parliament MB; Scrimger RA; Anderson SG; Kurien EC; Thompson HK; Field GC; Hanson J Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):663-73. PubMed ID: 14967418 [TBL] [Abstract][Full Text] [Related]
11. Scintigraphic assessment of salivary function after intensity-modulated radiotherapy for head and neck cancer: correlations with parotid dose and quality of life. Chen WC; Lai CH; Lee TF; Hung CH; Liu KC; Tsai MF; Wang WH; Chen H; Fang FM; Chen MF Oral Oncol; 2013 Jan; 49(1):42-8. PubMed ID: 22854066 [TBL] [Abstract][Full Text] [Related]
12. Salivary gland-sparing other than parotid-sparing in definitive head-and-neck intensity-modulated radiotherapy does not seem to jeopardize local control. Chajon E; Lafond C; Louvel G; Castelli J; Williaume D; Henry O; Jégoux F; Vauléon E; Manens JP; Le Prisé E; de Crevoisier R Radiat Oncol; 2013 May; 8():132. PubMed ID: 23721062 [TBL] [Abstract][Full Text] [Related]
13. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Nutting CM; Morden JP; Harrington KJ; Urbano TG; Bhide SA; Clark C; Miles EA; Miah AB; Newbold K; Tanay M; Adab F; Jefferies SJ; Scrase C; Yap BK; A'Hern RP; Sydenham MA; Emson M; Hall E; Lancet Oncol; 2011 Feb; 12(2):127-36. PubMed ID: 21236730 [TBL] [Abstract][Full Text] [Related]
14. Effect of dose to parotid ducts on Sticky Saliva and Xerostomia in radiotherapy of head and neck squamous cell carcinoma. Schanne DH; Alder DU; Lippmann J; Aebersold DM; Elicin O Radiat Oncol; 2024 Aug; 19(1):104. PubMed ID: 39095864 [TBL] [Abstract][Full Text] [Related]
15. Reducing Xerostomia by Comprehensive Protection of Salivary Glands in Intensity-Modulated Radiation Therapy with Helical Tomotherapy Technique for Head-and-Neck Cancer Patients: A Prospective Observational Study. Teng F; Fan W; Luo Y; Ju Z; Gong H; Ge R; Tong F; Zhang X; Ma L Biomed Res Int; 2019; 2019():2401743. PubMed ID: 31380414 [TBL] [Abstract][Full Text] [Related]
17. Can dose reduction to one parotid gland prevent xerostomia?--A feasibility study for locally advanced head and neck cancer patients treated with intensity-modulated radiotherapy. Anand AK; Jain J; Negi PS; Chaudhoory AR; Sinha SN; Choudhury PS; Kumar R; Munjal RK Clin Oncol (R Coll Radiol); 2006 Aug; 18(6):497-504. PubMed ID: 16909975 [TBL] [Abstract][Full Text] [Related]
18. Comparison of xerostomia incidence after three-dimensional conformal radiation therapy and contralateral superficial lobe parotid-sparing intensity-modulated radiotherapy for oropharyngeal and hypopharyngeal cancer. Kawamoto T; Nihei K; Nakajima Y; Kito S; Sasai K; Karasawa K Auris Nasus Larynx; 2018 Oct; 45(5):1073-1079. PubMed ID: 29397249 [TBL] [Abstract][Full Text] [Related]
19. Dose-volume modeling of salivary function in patients with head-and-neck cancer receiving radiotherapy. Blanco AI; Chao KS; El Naqa I; Franklin GE; Zakarian K; Vicic M; Deasy JO Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):1055-69. PubMed ID: 15990009 [TBL] [Abstract][Full Text] [Related]
20. The role of parotid gland irradiation in the development of severe hyposalivation (xerostomia) after intensity-modulated radiation therapy for head and neck cancer: Temporal patterns, risk factors, and testing the QUANTEC guidelines. Owosho AA; Thor M; Oh JH; Riaz N; Tsai CJ; Rosenberg H; Varthis S; Yom SH; Huryn JM; Lee NY; Deasy JO; Estilo CL J Craniomaxillofac Surg; 2017 Apr; 45(4):595-600. PubMed ID: 28256385 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]